Drug Trial Radar · NCT07905547
A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Oct 28, 2026
Primary completion
Feb 7, 2027
Study completion Aug 2, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will describe safety of dupilumab in adult participants with atopic dermatitis. It will also look at the improvement of atopic dermatitis signs and symptoms in these participants. The maximum study duration would be 32 weeks which includes the below: * Up to 28 days of screening period in which the doctor will assess if the participant can be recruited in this study * Treatment duration is 16 weeks * Follow up period: during which the participant will be followed for 12 weeks to check for any safety events. Visit frequency: The visit frequency will be every 4 weeks during the 16 weeks treatment duration and then 12 weeks after the last dose of the study treatment. Total number of visits will be 7.
Conditions
- Atopic Dermatitis
Interventions
DupilumabDrug
Each single-use pre-filled syringe with needle shield contains 300 mg dupilumab in 2 mL solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who Experienced Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 16
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.